Prague Med. Rep. 2012, 113, 105-118

https://doi.org/10.14712/23362936.2015.26

Topical Treatment Modalities for Old World Cutaneous Leishmaniasis: A Review

R. Alavi-Naini1, Asghar Fazaeli2, T. O'Dempsey3

1Research Centre for Infectious Diseases and Tropical Medicine, Zahedan University of Medical Sciences, Zahedan, Iran
2Department of Parasitology, School of Medicine, Zanjan University of Medical Sciences and Health Services, Zanjan, Iran
3Liverpool School of Tropical Medicine, Liverpool, UK

Received October 6, 2011
Accepted April 11, 2012

References

1. Aguiar, M. G., Silva, D. L., Nunan, F. A., Nunan, E. A., Fernandes, A. P., Ferreira, L. A. (2009) Combined topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) major leads to reduction in both lesion size and systemic parasite burdens. J. Antimicrob. Chemother. 64(6), 1234–1240. <https://doi.org/10.1093/jac/dkp365>
2. Akilov, O. E., Kosaka, S., O’Riordan, K., Song, X., Sherwood, M., Flotte, T. J., Foley, J. W., Hasan, T. (2006) The role of photosensitizer molecular charge and structure on the efficacy of photodynamic therapy against Leishmania parasites. Chem. Biol. 13(8), 839–847. <https://doi.org/10.1016/j.chembiol.2006.06.008>
3. Akilov, O. E., Kosaka, S., O’Riordan, K., Hasan, T. (2007) Photodynamic therapy for cutaneous leishmaniasis: The effectiveness of topical phenothiaziniums in parasite eradication and Th1 immune response stimulation. Photochem. Photobiol. Sci. 6(10), 1067–1075. <https://doi.org/10.1039/b703521g>
4. Alavi-Naini, R. (2008) Topical morphine for the treatment of cutaneous leishmaniasis. Med. Hypotheses 70(1), 81–84. <https://doi.org/10.1016/j.mehy.2007.04.027>
5. Alavi-Naini, R., Fazaeli, A., Pejman, B. M., Ansari, A., Fouladi, B., Khamesipour, A. (2010) The efficacy of morphine on murine (BALB/C) cutaneous leishmaniasis. Iran. J. Infect. Dis. Trop. Med. 14(46), 15–21.
6. al-Majali, O., Routh, H. B., Abuloham, O., Bhowmik, K. R., Muhsen, M., Hebeheba, H. (1997) A 2-year study of liquid nitrogen therapy in cutaneous leishmaniasis. Int. J. Dermatol. 36(6), 460–462. <https://doi.org/10.1046/j.1365-4362.1997.00045.x>
7. Al-Mutairi, N., Alshiltawy, M., El Khalawany, M., Joshi, A., Eassa, B. I., Manchanda, Y., Gomaa, S., Darwish, I., Rijhwani, M. (2009) Tropical medicine rounds: Treatment of Old World cutaneous leishmaniasis with dapsone, itraconazole, cryotherapy, and imiquimod, alone and in combination. Int. J. Dermatol. 48(8), 862–869. <https://doi.org/10.1111/j.1365-4632.2008.04010.x>
8. Amato, V. S., Rabello, A., Rotondo-Silva, A., Kono, A., Maldonado, T. P. H., Alves, I. C., Floeter-Winter, L. M., Neto, V. A., Shikanai-Yasuda, M. A. (2004) Successful treatment of cutaneous leishmaniasis with lipid formulations of amphotericin B in two immunocompromised patients. Acta Trop. 92(2), 127–132. <https://doi.org/10.1016/j.actatropica.2004.06.006>
9. Arana, B., Rizzo, N., Diaz, A. (2001a) Chemotherapy of cutaneous leishmaniasis: a review. Med. Microbiol. Immunol. 190(1–2), 93–95. <https://doi.org/10.1007/s004300100089>
10. Arana, B. A., Mendoza, C. E., Rizzo, N. R., Kroeger, A. (2001b) Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala. Am. J. Trop. Med. Hyg. 65(5), 466–470. <https://doi.org/10.4269/ajtmh.2001.65.466>
11. Arevalo, I., Ward, B., Miller, R., Tze-Chiang, M., Najar, E., Alvarez, E., Matlashewski, G., Llanos-Cuentas, A. (2001) Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin. Infect. Dis. 33(11), 1847–1851. <https://doi.org/10.1086/324161>
12. Arevalo, I., Tulliano, G., Quispe, A., Spaeth, G., Matlashewski, G., Llanos-Cuentas, A., Pollack, H. (2007) Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis. Clin. Infect. Dis. 44(12), 1549–1554. <https://doi.org/10.1086/518172>
13. Armijos, R. X., Weigel, M. M., Calvopina, M., Mancheno, M., Rodriguez, R. (2004) Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis. Acta Trop. 91(2), 153–160. <https://doi.org/10.1016/j.actatropica.2004.03.009>
14. Aronson, N. E., Wortmann, G. W., Byrne, W. R., Howard, R. S., Bernstein, W. B., Marovich, M. A., Polhemus, M. E., Yoon, I. K., Hummer, K. A., Gasser, R. A. Jr., Oster, C. N., Benson, P. M. (2010) A randomized controlled trial of local heat therapy versus intravenous sodium stibogluconate for the treatment of cutaneous Leishmania major infection. PLoS Negl. Trop. Dis. 4(3), e628. <https://doi.org/10.1371/journal.pntd.0000628> <PubMed>
15. Asilian, A., Davami, M. (2006) Comparison between the efficacy of photodynamic therapy and topical paromomycin in the treatment of Old World cutaneous leishmaniasis: a placebo-controlled, randomized clinical trial. Clin. Exp. Dermatol. 31(5), 634–637. <https://doi.org/10.1111/j.1365-2230.2006.02182.x>
16. Asilian, A., Jalayer, T., Nilforooshzadeh, M., Ghassemi, R. L., Peto, R., Wayling, S., Olliaro, P., Modabber, F. (2003) Treatment of cutaneous leishmaniasis with aminosidine (paromomycin) ointment: double-blind, randomized trial in the Islamic Republic of Iran. Bull. World Health Organ. 81(5), 353–359.
17. Asilian, A., Sadeghinia, A., Faghihi, G., Momeni, A. (2004a) Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis. Int. J. Dermatol. 43(4), 281–283. <https://doi.org/10.1111/j.1365-4632.2004.02002.x>
18. Asilian, A., Sharif, A., Faghihi, G., Enshaeieh, S., Shariati, F., Siadat, A. H. (2004b) Evaluation of CO2 laser efficacy in the treatment of cutaneous leishmaniasis. Int. J. Dermatol. 43(10), 736–738. <https://doi.org/10.1111/j.1365-4632.2004.02349.x>
19. Asilian, A., Iraji, F., Hedaiti, H. R., Siadat, A. H., Enshaieh, S. (2006) Carbon dioxide laser for the treatment of lupoid cutaneous leishmaniasis (LCL): a case series of 24 patients. Dermatol. Online J. 12(2), 3.
20. Bassiouny, A., El Meshad, M., Talaat, M., Kutty, K., Metawaa, B. (1982) Cryosurgery in cutaneous leishmaniasis. Br. J. Dermatol. 107(4), 467–474. <https://doi.org/10.1111/j.1365-2133.1982.tb00390.x>
21. Beyrer, C., Villar, J. C., Suwanvanichkij, V., Singh, S., Baral, S. D., Mills, E. J. (2007). Neglected diseases, civil conflicts, and the right to health. Lancet 370(9587), 619–627. <https://doi.org/10.1016/S0140-6736(07)61301-4>
22. Bumb, R. A., Satoskar, A. R. (2011) Radiofrequency-induced heat therapy as first-line treatment for cutaneous leishmaniasis. Expert Rev. Anti Infect. Ther. 9(6), 623–625. <https://doi.org/10.1586/eri.11.50>
23. Carneiro, G., Santos, D. C., Oliveira, M. C., Fernandes, A. P., Ferreira, L. S., Ramaldes, G. A., Nunan, E. A., Ferreira, L. A. (2010) Topical delivery and in vivo antileishmanial activity of paromomycin-loaded liposomes for treatment of cutaneous leishmaniasis. J. Liposome Res. 20(1), 16–23. <https://doi.org/10.3109/08982100903015025>
24. Croft, S. L., Yardley, V. (2002) Chemotherapy of leishmaniasis. Curr. Pharm. Des. 8(4), 319–342. <https://doi.org/10.2174/1381612023396258>
25. Croft, S. L., Sundar, S., Fairlamb, A. H. (2006) Drug resistance in leishmaniasis. Clin. Microbiol. Rev. 19(1), 111–126. <https://doi.org/10.1128/CMR.19.1.111-126.2006> <PubMed>
26. Davidson, R. N., Russo, R. (1994) Relapse of visceral leishmaniasis in patients who were coinfected with human immunodeficiency virus and who received treatment with liposomal amphotericin B. Clin. Infect. Dis. 19(3), 560. <https://doi.org/10.1093/clinids/19.3.560>
27. Davidson, R. N., Yardley, V., Croft, S. L., Konecny, P., Benjamin, N. (2000) A topical nitric oxide-generating therapy for cutaneous leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 94(3), 319–322. <https://doi.org/10.1016/S0035-9203(00)90341-9>
28. de Souza, G. F., Yokoyama-Yasunaka, J. K., Seabra, A. B., Miguel, D. C., de Oliveira, M. G., Uliana, S. R. (2006) Leishmanicidal activity of primary S-nitrosothiols against Leishmania major and Leishmania amazonensis: implications for the treatment of cutaneous leishmaniasis. Nitric Oxide 15(3), 209–216. <https://doi.org/10.1016/j.niox.2006.01.011>
29. Dutta, S., Ray, D., Kolli, B. K., Chang, K. P. (2005) Photodynamic sensitization of Leishmania amazonensis in both extracellular and intracellular stages with aluminum phthalocyanine chloride for photolysis in vitro. Antimicrob. Agents Chemother. 49(11), 4474–4484. <https://doi.org/10.1128/AAC.49.11.4474-4484.2005> <PubMed>
30. el Darouti, M. A., al Rubaie, S. M. (1990) Cutaneous leishmaniasis. Treatment with combined cryotherapy and intralesional stibogluconate injection. Int. J. Dermatol. 29(1), 56–59. <https://doi.org/10.1111/j.1365-4362.1990.tb03759.x>
31. El-On, J., Jacobs, G. P., Witztum, E., Greenblatt, C. L. (1984) Development of topical treatment for cutaneous leishmaniasis caused by Leishmania major in experimental animals. Antimicrob. Agents Chemother. 26(5), 745–751. <https://doi.org/10.1128/AAC.26.5.745>
32. El-On, J., Halevy, S., Grunwald, M. H., Weinrauch, L. (1992) Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: a double-blind control study. J. Am. Acad. Dermatol. 27(2 Pt 1), 227–231. <https://doi.org/10.1016/0190-9622(92)70175-F>
33. Faghihi, G., Tavakoli-kia, R. (2003) Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate. Clin. Exp. Dermatol. 28(1), 13–16. <https://doi.org/10.1046/j.1365-2230.2003.01169.x>
34. Fazaeli, A., Fouladi, B., Hashemi-Shahri, S. M., Sharifi, I. (2008) Clinical features of cutaneous leishmaniasis and direct PCR based identification of parasite species in a new focus in south-east of Iran. Iranian J. Publ. Health 37, 44–51.
35. Fazaeli, A., Fouladi, B., Sharifi, I. (2009) Emergence of cutaneous leishmaniasis in a border area at south-east of Iran: an epidemiological survey. J. Vector Borne Dis. 46(1), 36–42.
36. Fernández, M. M., Malchiodi, E. L., Algranati, I. D. (2011) Differential effects of paromomycin on ribosomes of Leishmania mexicana and mammalian cells. Antimicrob. Agents Chemother. 55(1), 86–93. <https://doi.org/10.1128/AAC.00506-10> <PubMed>
37. Firooz, A., Khamesipour, A., Ghoorchi, M. H., Nassiri-Kashani, M., Eskandari, S. E., Khatami, A., Hooshmand, B., Gorouhi, F., Rashighi-Firoozabadi, M., Dowlati, Y. (2006) Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial. Arch. Dermatol. 142(12), 1575–1579.
38. Fouladi, B., Sharifi, I., Hashemi Shahri, M., Moradgholi, H. R., Sarabandi-No, A., Ebrahimzadeh, A., Fazaeli, A. (2007) Evaluation of a direct PCR in comparison with routine microscopy and in vitro culture for diagnosis of cutaneous leishmaniasis. J. Zahedan Univ. Med. Sci. Health Serv. 9(3), 181–189.
39. Frankenburg, S., Glick, D., Klaus, S., Barenholz, Y. (1998) Efficacious topical treatment for murine cutaneous leishmaniasis with ethanolic formulations of amphotericin B. Antimicrob. Agents Chemother. 42(12), 3092–3096. <https://doi.org/10.1128/AAC.42.12.3092>
40. Garnier, T., Brown, M. B., Lawrence, M. J., Croft, S. L. (2006) In-vitro and in-vivo studies on a topical formulation of sitamaquine dihydrochloride for cutaneous leishmaniasis. J. Pharm. Pharmacol. 58(8), 1043–1054. <https://doi.org/10.1211/jpp.58.8.0004>
41. Garnier, T., Mantyla, A., Jarvinen, T., Lawrence, J., Brown, M., Croft, S. (2007) In vivo studies on the antileishmanial activity of buparvaquone and its prodrugs. J. Antimicrob. Chemother. 60(4), 802–810. <https://doi.org/10.1093/jac/dkm303>
42. Glasser, J. S., Murray, C. K. (2011) Central nervous system toxicity associated with liposomal amphotericin B therapy for cutaneous leishmaniasis. Am. J. Trop. Med. Hyg. 84(4), 566–568. <https://doi.org/10.4269/ajtmh.2011.10-0662> <PubMed>
43. González, U., Pinart, M., Reveiz, L., Alvar, J. (2008) Interventions for Old World cutaneous leishmaniasis. Cochrane Database Syst. Rev. (4), CD005067.
44. Grogl, M., Schuster, B. G., Ellis, W. Y., Berman, J. D. (1999) Successful topical treatment of murine cutaneous leishmaniasis with a combination of paromomycin (Aminosidine) and gentamicin. J. Parasitol. 85(2), 354–359. <https://doi.org/10.2307/3285646>
45. Iraji, F., Sadeghinia, A. (2005) Efficacy of paromomycin ointment in the treatment of cutaneous leishmaniasis: results of a double-blind, randomized trial in Isfahan, Iran. Ann. Trop. Med. Parasitol. 99(1), 3–9. <https://doi.org/10.1179/136485905X16372>
46. Jha, T. K., Sundar, S., Thakur, C. P., Felton, J. M., Sabin, A. J., Horton, J. (2005) A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India. Am. J. Trop. Med. Hyg. 73(6), 1005–1011. <https://doi.org/10.4269/ajtmh.2005.73.1005>
47. Jowkar, F., Dehghani, F., Jamshidzadeh, A. (2012) Is topical nitric oxide and cryotherapy more effective than cryotherapy in the treatment of old world cutaneous leishmaniasis? J. Dermatolog. Treat. 23(2), 131–135. <https://doi.org/10.3109/09546634.2010.495380>
48. Khalili, G., Dobakhti, F., Mahmoudzadeh-Niknam, H., Khaze, V., Partovi, F. (2011) Immunotherapy with Imiquimod increases the efficacy of Glucantime therapy of Leishmania major infection. Iran. J. Immunol. 8(1), 45–51.
49. Larbi, E. B., al-Khawajah, A., al-Gindan, Y., Jain, S., Abahusain, A., al-Zayer, A. (1995) A randomized, doubleblind, clinical trial of topical clotrimazole versus miconazole for treatment of cutaneous leishmaniasis in the eastern province of Saudi Arabia. Am. J. Trop. Med. Hyg. 52(2), 166–168. <https://doi.org/10.4269/ajtmh.1995.52.166>
50. Layegh, P., Pezeshkpoor, F., Soruri, A. H., Naviafar, P., Moghiman, T. (2009) Efficacy of cryotherapy versus intralesional meglumine antimoniate (glucantime) for treatment of cutaneous leishmaniasis in children. Am. J. Trop. Med. Hyg. 80(2), 172–175. <https://doi.org/10.4269/ajtmh.2009.80.172>
51. Layegh, P., Rajabi, O., Jafari, M. R., Emamgholi Tabar Malekshah, P., Moghiman, T., Ashraf, H., Salari, R. (2011) Efficacy of topical liposomal amphotericin B versus intralesional meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis. J. Parasitol. Res. 2011, 656523. (Epub) <https://doi.org/10.1155/2011/656523> <PubMed>
52. Lee, Y., Baron, E. D. (2011) Photodynamic therapy: current evidence and applications in dermatology. Semin. Cutan. Med. Surg. 30(4), 199–209. <https://doi.org/10.1016/j.sder.2011.08.001>
53. Leibovici, V., Aram, H. (1986) Cryotherapy in acute cutaneous leishmaniasis. Int. J. Dermatol. 25(7), 473–475. <https://doi.org/10.1111/j.1365-4362.1986.tb03461.x>
54. Loiseau, P. M., Cojean, S., Schrével, J. J. (2011) Sitamaquine as a putative antileishmanial drug candidate: from the mechanism of action to the risk of drug resistance. Parasite 18(2), 115–119. <https://doi.org/10.1051/parasite/2011182115> <PubMed>
55. Lusby, P. E., Coombes, A., Wilkinson, J. M. (2002) Honey: a potent agent for wound healing? J. Wound Ostomy Continence Nurs. 29(6), 295–300.
56. Lusby, P. E., Coombes, A. L., Wilkinson, J. M. (2005) Bactericidal activity of different honeys against pathogenic bacteria. Arch. Med. Res. 36(5), 464–467. <https://doi.org/10.1016/j.arcmed.2005.03.038>
57. Mantyla, A., Garnier, T., Rautio, J., Nevalainen, T., Vepsälainen, J., Koskinen, A., Croft, S. L., Järvinen, T. (2004) Synthesis, in vitro evaluation, and antileishmanial activity of water-soluble prodrugs of buparvaquone. J. Med. Chem. 47(1), 188–195. <https://doi.org/10.1021/jm030868a>
58. Miranda-Verastegui, C., Llanos-Cuentas, A., Arevalo, I., Ward, B. J., Matlashewski, G. (2005) Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru. Clin. Infect. Dis. 40(10), 1395–1403. <https://doi.org/10.1086/429238>
59. Momeni, A. Z., Aminjavaheri, M. (2000) A double-blind randomized clinical trial of a topical herbal extract (Z-he) vs. systemic meglumine antimonate. Int. J. Dermatol. 39(11), 880. <https://doi.org/10.1046/j.1365-4362.2000.00914-8.x>
60. Munir, A., Janjua, S. A., Hussain, I. (2008) Clinical efficacy of intramuscular meglumine antimoniate alone and in combination with intralesional meglumine antimoniate in the treatment of old world cutaneous leishmaniasis. Acta Dermatovenerol. Croat. 16(2), 60–64.
61. Mussi, S. V., Fernandes, A. P., Ferreira, L. A. (2007) Comparative study of the efficacy of formulations containing fluconazole or paromomycin for topical treatment of infections by Leishmania (Leishmania) major and Leishmania (Leishmania) amazonensis. Parasitol. Res. 100(6), 1221–1226. <https://doi.org/10.1007/s00436-006-0394-6>
62. Neva, F. A., Ponce, C., Ponce, E., Kreutzer, R., Modabber, F., Olliaro, P. (1997) Non-ulcerative cutaneous leishmaniasis in Honduras fails to respond to topical paromomycin. Trans. R. Soc. Trop. Med. Hyg. 91(4), 473–475. <https://doi.org/10.1016/S0035-9203(97)90290-X>
63. Nilforoushzadeh, M. A., Jaffary, F., Moradi, S., Derakhshan, R., Haftbaradaran, E. (2007) Effect of topical honey application along with intralesional injection of glucantime in the treatment of cutaneous leishmaniasis. BMC Complement. Altern. Med. 7, 13. <https://doi.org/10.1186/1472-6882-7-13> <PubMed>
64. Ouellette, M., Drummelsmith, J., Papadopoulou, B. (2004) Leishmaniasis: drugs in the clinic, resistance and new developments. Drug Resist. Update. 7, 257–266. <https://doi.org/10.1016/j.drup.2004.07.002>
65. Panagiotopoulos, A., Stavropoulos, P. G., Hasapi, V., Papakonstantinou, A. M., Petridis, A., Katsambas, A. (2005) Treatment of cutaneous leishmaniasis with cryosurgery. Int. J. Dermatol. 44(9), 749–752. <https://doi.org/10.1111/j.1365-4632.2005.02628.x>
66. Proffitt, R. T., Satorius, A., Chiang, S. M., Sullivan, L., Adler-Moore, J. P. (1991) Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J. Antimicrob. Chemother. 28, 49–61 (Suppl. B). <https://doi.org/10.1093/jac/28.suppl_B.49>
67. Reithinger, R., Mohsen, M., Aadil, K., Sidiqi, M., Erasmus, P., Coleman, P. G. (2003) Anthroponotic cutaneous leishmaniasis, Kabul, Afghanistan. Emerg. Infect. Dis. 9(6), 727–729. <https://doi.org/10.3201/eid0906.030026> <PubMed>
68. Reithinger, R., Mohsen, M., Wahid, M., Bismullah, M., Quinnell, R. J., Davies, C. R., Kolaczinski, J., David, J. R. (2005) Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, controlled trial. Clin. Infect. Dis. 40(8), 1148–1155. <https://doi.org/10.1086/428736>
69. Reithinger, R., Dujardin, J. C., Louzir, H., Pirmez, C., Alexander, B., Brooker, S. (2007) Cutaneous leishmaniasis. Lancet Infect. Dis. 7(9), 581–596. <https://doi.org/10.1016/S1473-3099(07)70209-8>
70. Rodrigues, A. M., Hueb, M., Santos, T. A., Fontes, C. J. (2006) Factors associated with treatment failure of cutaneous leishmaniasis with meglumine antimoniate. Rev. Soc. Bras. Med. Trop. 39(2), 139–145. <https://doi.org/10.1590/S0037-86822006000200001>
71. Seeberger, J., Daoud, S., Pammer, J. (2003) Transient effect of topical treatment of cutaneous leishmaniasis with imiquimod. Int. J. Dermatol. 42(7), 576–579. <https://doi.org/10.1046/j.1365-4362.2003.01955.x>
72. Shamsi Meymandi, S., Zandi, S., Aghaie, H., Heshmatkhah, A. (2011) Efficacy of CO(2) laser for treatment of anthroponotic cutaneous leishmaniasis, compared with combination of cryotherapy and intralesional meglumine antimoniate. J. Eur. Acad. Dermatol. Venereol. 25(5), 587–591. <https://doi.org/10.1111/j.1468-3083.2010.03781.x>
73. Shazad, B., Abbaszadeh, B., Khamesipour, A. (2005) Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major. Eur. J. Dermatol. 15(2), 85–87.
74. Singh, S.,Sivakumar, R. (2004) Challenges and new discoveries in the treatment of leishmaniasis. J. Infect. Chemother. 10(6), 307–315. <https://doi.org/10.1007/s10156-004-0348-9>
75. Stanimirovic, A., Stipic, T., Skerlev, M., Basta-Juzbasic, A. (1999) Treatment of cutaneous leishmaniasis with 20% paromomycin ointment. J. Eur. Acad. Dermatol. Venereol. 13(3), 214–217. <https://doi.org/10.1111/j.1468-3083.1999.tb00886.x>
76. Stevens, D. A. (1994) Overview of amphotericin B colloidal dispersion (amphocil). J. Infect. 28, 45–49 (Suppl. 1). <https://doi.org/10.1016/S0163-4453(94)95971-4>
77. Storer, E., Wayte, J. (2005) Cutaneous leishmaniasis in Afghani refugees. Australas. J. Dermatol. 46(2), 80–83. <https://doi.org/10.1111/j.1440-0960.2005.00146.x>
78. Sundar, S., Rai, M. (2002) Advances in the treatment of leishmaniasis. Curr. Opin. Infect. Dis. 15(6), 593–598. <https://doi.org/10.1097/00001432-200212000-00007>
79. Sundar, S., Jha, T. K., Thakur, C. P., Mishra, M., Singh, V. P., Buffels, R. (2003) Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin. Infect. Dis. 37(6), 800–804. <https://doi.org/10.1086/377542>
80. Sundar, S., Chakravarty, J., Rai, V. K., Agrawal, N., Singh, S. P., Chauhan, V., Murray, H. W. (2007) Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions. Clin. Infect. Dis. 45(5), 556–561. <https://doi.org/10.1086/520665>
81. Uzun, S., Durdu, M., Culha, G., Allahverdiyev, A. M., Memisoglu, H. R. (2004) Clinical features, epidemiology, and efficacy and safety of intralesional antimony treatment of cutaneous leishmaniasis: recent experience in Turkey. J. Parasitol. 90(4), 853–859. <https://doi.org/10.1645/GE-185R>
82. van Thiel, P. P., Leenstra, T., de Vries, H. J., van der Sluis, A., van Gool, T., Krull, A. C., van Vugt, M., de Vries, P. J., Zeegelaar, J. E., Bart, A., van der Meide, W. F., Schallig, H. D., Faber, W. R., Kager, P. A. (2010) Cutaneous leishmaniasis (Leishmania major infection) in Dutch troops deployed in northern Afghanistan: epidemiology, clinical aspects, and treatment. Am. J. Trop. Med. Hyg. 83(6), 1295–1300. <https://doi.org/10.4269/ajtmh.2010.10-0143> <PubMed>
83. Vega, J. C., Sanchez, B. F., Montero, L. M., Montaña, R., del Pilar Mahecha, M., Dueñes, B., Baron, A. R., Reithinger, R. (2009) The efficacy of thermotherapy to treat cutaneous leishmaniasis in Colombia: a comparative observational study in an operational setting. Trans. R. Soc. Trop. Med. Hyg. 103(7), 703–706. <https://doi.org/10.1016/j.trstmh.2008.10.039>
84. Wasan, K. M., Sivak, O., Rosland, M., Risovic, V., Bartlett, K. (2007) Assessing the antifungal activity, pharmacokinetics, and tissue distribution of amphotericin B following the administration of Abelcet and AmBisome in combination with caspofungin to rats infected with Aspergillus fumigatus. J. Pharm. Sci. 96(7), 1737–1747. <https://doi.org/10.1002/jps.20801>
85. Yaghoobi-Ershadi, M. R., Jafari, R., Hanafi-Bojd, A. A. (2004) A new epidemic focus of zoonotic cutaneous leishmaniasis in central Iran. Ann. Saudi Med. 24(2), 98–101. <https://doi.org/10.5144/0256-4947.2004.98> <PubMed>
86. Zeina, B., Zohra, B. I., al-Assad, S. (1997a) Topical glyceryl trinitrate: a possible treatment for cutaneous leishmaniasis. Clin. Exp. Dermatol. 22(5), 244–245. <https://doi.org/10.1111/j.1365-2230.1997.tb01079.x>
87. Zeina, B., Banfield, C., al-Assad, S. (1997b) The effects of honey on Leishmania parasites: an in vitro study. Trop. Doct. 27, 36–38 (Suppl. 1).
88. Zerehsaz, F., Salmanpour, R., Hanjani, F., Ardehali, S., Panjehshahin, M. R., Tabei, S. Z., Tabatabaee, H. R. (1999) A double-blind randomized clinical trial of a topical herbal extract (Z-HE) vs. systemic meglumine antimoniate for the treatment of cutaneous leishmaniasis in Iran. Int. J. Dermatol. 38, 610–612. <https://doi.org/10.1046/j.1365-4362.1999.00727.x>
89. Zvulunov, A., Cagnano, E., Frankenburg, S., Barenholz, Y., Vardy, D. (2003) Topical treatment of persistent cutaneous leishmaniasis with ethanolic lipid amphotericin B. Pediatr. Infect. Dis. J. 22(6), 567–569.
front cover

ISSN 1214-6994 (Print) ISSN 2336-2936 (Online)

Archive